HERVolution Therapeutics, a Copenhagen, Denmark-based dark genome-focused biotechnology company, raised $11.7M in Series A funding.
The round was led by Serum Institute of India (SII) with participation from the European Innovation Council (EIC) Fund and other investors.
The company intends to use the funds to support key activities, including further validating and demonstrating the value of its human endogenous retroviruses (HERV)-targeting approach, cGMP manufacturing in collaboration with SII, initiating Phase 1 studies of its lead asset, investigating indication expansion opportunities, and expanding company infrastructure to support clinical trials.
Led by J. Robert Coleman, PhD, MBA, Chief Executive Officer, HERVolution Therapeutics (formerly InProTher Aps) is a dark genome-focused biotechnology company providing new human endogenous retrovirus (HERV)-targeted immunotherapies to address diseases of aging. With its proprietary engineering approaches, it has rationally redesigned HERV-antigens to yield a new class of highly immunogenic antigens to address cancer, metabolic, and other aging-related diseases. Its team has advanced a strong product development pipeline, with lead program, IPT-001, anticipated to enter the clinic in 2025.
FinSMEs
19/12/2024